Affiliation:
1. Division on Substance Use Disorders New York State Psychiatric Institute New York New York USA
2. Department of Psychiatry Columbia University Irving Medical Center New York New York USA
3. Global Medicines Development Indivior Inc. Richmond Virginia USA
4. Hassman Research Institute CenExel Berlin New Jersey USA
Abstract
AbstractBackground and ObjectivesSynthetic opioids, including fentanyl and fentanyl analogs, account for over 70,000 annual overdose deaths in the United States, but there is limited information examining methods of induction and maintenance outcomes for buprenorphine treatment of patients with opioid use disorder (OUD) using these opioids.MethodsA secondary analysis of results grouped by fentanyl use status was completed for an open‐label study with rapid induction of extended‐release buprenorphine in the inpatient research unit. Eligible participants received a single 4 mg dose of transmucosal buprenorphine (BUP‐TM) followed by an extended‐release buprenorphine 300 mg injection ([BUP‐XR]) after approximately 1 h. An extension study continued follow‐up up to 6 months (6 monthly injections).ResultsAmong participants with fentanyl‐positive urine samples (FEN+; n = 19), all received BUP‐TM, 17 received BUP‐XR, 13 elected to receive a second BUP‐XR injection, and 10 received all six scheduled injections. Among participants with fentanyl‐negative samples (FEN−; n = 7), all received BUP‐TM and BUP‐XR, four elected to receive a second injection, and two participants received all six scheduled injections. Induction day clinical opioid withdrawal scale (COWS) scores were similar for FEN+ and FEN− groups. In the FEN+ group, mean COWS scores fell to below 5 within 24 h of BUP‐XR injection.Discussion and ConclusionsThe treatment of individuals with OUD using fentanyl with a rapid 1‐day induction to BUP‐XR 300 mg injection is feasible and well‐tolerated.Scientific SignificanceA prospective trial of participants grouped by fentanyl use status at induction demonstrates comparable patient retention and clinical response following single‐day induction of BUP‐XR in participants who are FEN+ and FEN−.
Subject
Psychiatry and Mental health,Clinical Psychology,Medicine (miscellaneous)
Reference31 articles.
1. Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. In: Quality CfBHSa ed. Vol HHS Publication No. PEP21‐07‐01‐003. Rockville MD: Substance Abuse and Mental Health Services Administration; 2021.
2. AhmadF RossenL SuttonP. Provisional drug overdose death counts. In: Statistics NCfH; 2022.
3. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review
4. Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors
5. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs